Topical high concentration oxygen with hyaluronic acid: A safe and effective treatment for vaginal atrophy and sexual function improvement

Post Reprod Health. 2025 Mar;31(1):9-21. doi: 10.1177/20533691241307804. Epub 2024 Dec 15.

Abstract

BackgroundGenitourinary syndrome of menopause (GSM) is a condition affecting many postmenopausal women. Among the available treatments, the vaginal natural oxygenation device (VNOD) is a new promising option.AimTo evaluate the safety and the effectiveness of vaginal high concentration (HC) oxygen (O2) and hyaluronic acid (HA) in postmenopausal women with vaginal atrophy (VA).MethodsStudy 1: Ten subjects received HA and O2 at a concentration of 21% (sham group) and ten at 95% (treatment group). All subjects completed five sessions of VNOD. Evaluations and questionnaires were completed at baseline, before each session and at one-month follow-up: Visual Analogue Scale, Vaginal Health Index (VHI), Vaginal Maturation Value (VMV), Menopause Quality Of Life (MeNQoL), Female sexual function index (FSFI) and Female sexual distress scale (FSDS). Study 2: 52 postmenopausal women with VA completed the same protocol of study 1 with HC O2 and HA.ResultsTreatment was well-tolerated. In study 1, in the treatment group we recorded significant improvements in VHI score (p-value 0.001), VMV (p-value 0.005) and in the psychosocial, physical and sexual domains of the MeNQoL compared to sham group. In study 2, all women experienced a significant improvement in VHI (p-value <0.001), FSFI total score (p-value 0.007), desire (p-value 0.004), lubrication (p-value 0.006), satisfaction (p-value 0.042), pain (p-value 0.001) domains, FSDS score (p-value 0.003) and MeNQoL sexual domain (p-value <0.001).ConclusionThe preliminary results of this study suggest that VNOD is a safe and effective treatment for VA in postmenopausal women, and improves sexual function.

Keywords: VNOD; female sexual function; hyaluronic acid; oxygen; vaginal atrophy; vaginal health index.

MeSH terms

  • Administration, Intravaginal
  • Atrophy / drug therapy
  • Female
  • Humans
  • Hyaluronic Acid* / administration & dosage
  • Hyaluronic Acid* / therapeutic use
  • Middle Aged
  • Oxygen* / administration & dosage
  • Postmenopause
  • Quality of Life
  • Sexual Dysfunction, Physiological* / drug therapy
  • Surveys and Questionnaires
  • Treatment Outcome
  • Vagina* / drug effects
  • Vagina* / pathology
  • Vaginal Diseases* / drug therapy
  • Vaginal Diseases* / pathology

Substances

  • Hyaluronic Acid
  • Oxygen